May 06, 2018 - Teva reported market-beating Q1 2018 results before the market opened on Thursday, but its share price eventually ended the day down 4.4 percent.An upward revision to the 2018 guidance also failed to
May 05, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
May 04, 2018 - Kiniksa Pharma has filed an initial registration statement for a U.S. IPO.The firm is a mid-stage developer of treatments for autoimmune and inflammatory diseases.KNSA shows promise but the IPO is unu
May 04, 2018 - Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
May 04, 2018 - Significant hires, partnership activity, and an important data readout later this year point towards an inflection point in ATNM.We believe that the company's drug candidates benefit from significant
May 02, 2018 - Allergan spends entirely too much time discussing strategic alternatives for a growing business.The company continues to shake off LOE issues with expectations to grow EPS.The Botox market is expected
May 02, 2018 - Miracle Mile Advisors, LLC Buys First Trust Preferred Securities and Income ETF, Vanguard FTSE Developed Markets, iShares California Muni Bond, Sells WisdomTree Europe Hedged Equity Fund, iShares S&P 500 Value, iShares 1-3 Year Credit Bond ETF, Stocks: VEA,IEMG,AAPL,AGN,GOOGL,FB,FPE,CMF,SCZ,IXC,BAC,AMZ, release date:May 02, 2018
May 02, 2018 - KPTI is up on strong data from MM study.Allergan writes off its entire Vitae acquisition.Celgene is down on ozanimod resubmission delay.
May 02, 2018 - Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.
May 02, 2018 - Allergan announces write off for drug purchased from Vitae to treat psoriasis.The recent trial success for the acute migraine study should overshadow this bad news about abandonment of the psoriasis p